Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,659.90.
30 Oct: open ₹1,652.00, high ₹1,687.00, low ₹1,647.20
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹96,744 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.06
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,52,65057.5% delivered
Aurobindo Pharma analyst meets
220 filed, newest first. Page 4 of 5.
Aug 2020
10 Aug · Analysts
Jun 2020
18 Jun · Analysts
1 Jun · Analysts
Feb 2020
24 Feb · Analysts
15 Feb · Analysts
3 Feb · Analysts
Jan 2020
14 Jan · Analysts
Nov 2019
28 Nov · Analysts
14 Nov · Analysts
8 Nov · Analysts
Sep 2019
17 Sep · Analysts
Aug 2019
21 Aug · Analysts
19 Aug · Analysts
8 Aug · Analysts
5 Aug · Analysts
Jun 2019
14 Jun · Analysts
3 Jun · Analysts
May 2019
30 May · Analysts
24 May · Analysts
Mar 2019
26 Mar · Analysts
Feb 2019
22 Feb · Analysts
18 Feb · Analysts
14 Feb · Analysts
5 Feb · Analysts
Jan 2019
7 Jan · Analysts
Nov 2018
26 Nov · Analysts
15 Nov · Analysts
9 Nov · Analysts
Sep 2018
26 Sep · Analysts
19 Sep · Analysts
12 Sep · Analysts
6 Sep · Analysts
Aug 2018
24 Aug · Analysts
20 Aug · Analysts
20 Aug · Analysts
7 Aug · Analysts
Jun 2018
18 Jun · Analysts
May 2018
31 May · Analysts
28 May · Analysts
Mar 2018
20 Mar · Analysts
Feb 2018
26 Feb · Analysts
21 Feb · Analysts
21 Feb · Analysts
3 Feb · Analysts
Nov 2017
22 Nov · Analysts
4 Nov · Analysts
Sep 2017
25 Sep · Analysts
20 Sep · Analysts
4 Sep · Analysts
Aug 2017
23 Aug · Analysts